| Mr David J Itkin, MD | |
|
330 Borthwick Ave, Suite 210, Portsmouth, NH 03801-4174 | |
| (603) 433-8733 | |
| (603) 433-8834 |
| Full Name | Mr David J Itkin |
|---|---|
| Gender | Male |
| Speciality | Infectious Disease |
| Experience | 44 Years |
| Location | 330 Borthwick Ave, Portsmouth, New Hampshire |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1760476667 | NPI | - | NPPES |
| 3082964 | Medicaid | NH |
| Facility Name | Location | Facility Type |
|---|---|---|
| Valley View Hospital Association | Glenwood springs, CO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Valley View Hospital Association | 1850294778 | 167 |
News Archive
In a study of more than 1.3 million Kaiser Permanente members in Northern California that stretched over 10 years, researchers found that blacks, Latinos and Asians generally had lower risk of coronary heart disease compared to whites.
Results for a pilot registry on the management and treatment of atrial fibrillation in Europe were presented yesterday by the European Society of Cardiology. AF is the commonest cardiac rhythm disorder and each of us have a one-in-four lifetime risk of developing it. Statistics show that oral anticoagulant use has increased, but new oral anticoagulant use is still low. Authors also concluded that compliance with treatment guidelines for patients with the lowest and higher stroke risk scores remains suboptimal.
Jennerex, Inc., a clinical-stage biotherapeutics company focused on the development of first-in-class, targeted oncolytic products for cancer, today reported positive interim data from a pilot trial using JX-594 followed by sorafenib (Nexavar®) to treat liver cancer patients. The data were presented today at the Fourth Annual International Liver Cancer Association Conference in Montreal, Canada.
To combat the obesity epidemic, the National Institutes of Health is encouraging diverse scientific investigations through a new Strategic Plan for NIH Obesity Research.
› Verified 6 days ago
| Entity Name | Prowers County Hospital District |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821052929 PECOS PAC ID: 4486568508 Enrollment ID: O20031113000509 |
News Archive
In a study of more than 1.3 million Kaiser Permanente members in Northern California that stretched over 10 years, researchers found that blacks, Latinos and Asians generally had lower risk of coronary heart disease compared to whites.
Results for a pilot registry on the management and treatment of atrial fibrillation in Europe were presented yesterday by the European Society of Cardiology. AF is the commonest cardiac rhythm disorder and each of us have a one-in-four lifetime risk of developing it. Statistics show that oral anticoagulant use has increased, but new oral anticoagulant use is still low. Authors also concluded that compliance with treatment guidelines for patients with the lowest and higher stroke risk scores remains suboptimal.
Jennerex, Inc., a clinical-stage biotherapeutics company focused on the development of first-in-class, targeted oncolytic products for cancer, today reported positive interim data from a pilot trial using JX-594 followed by sorafenib (Nexavar®) to treat liver cancer patients. The data were presented today at the Fourth Annual International Liver Cancer Association Conference in Montreal, Canada.
To combat the obesity epidemic, the National Institutes of Health is encouraging diverse scientific investigations through a new Strategic Plan for NIH Obesity Research.
› Verified 6 days ago
| Entity Name | Valley View Hospital Association |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730897109 PECOS PAC ID: 1850294778 Enrollment ID: O20040129000027 |
News Archive
In a study of more than 1.3 million Kaiser Permanente members in Northern California that stretched over 10 years, researchers found that blacks, Latinos and Asians generally had lower risk of coronary heart disease compared to whites.
Results for a pilot registry on the management and treatment of atrial fibrillation in Europe were presented yesterday by the European Society of Cardiology. AF is the commonest cardiac rhythm disorder and each of us have a one-in-four lifetime risk of developing it. Statistics show that oral anticoagulant use has increased, but new oral anticoagulant use is still low. Authors also concluded that compliance with treatment guidelines for patients with the lowest and higher stroke risk scores remains suboptimal.
Jennerex, Inc., a clinical-stage biotherapeutics company focused on the development of first-in-class, targeted oncolytic products for cancer, today reported positive interim data from a pilot trial using JX-594 followed by sorafenib (Nexavar®) to treat liver cancer patients. The data were presented today at the Fourth Annual International Liver Cancer Association Conference in Montreal, Canada.
To combat the obesity epidemic, the National Institutes of Health is encouraging diverse scientific investigations through a new Strategic Plan for NIH Obesity Research.
› Verified 6 days ago
| Entity Name | Einfectionmd Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417437526 PECOS PAC ID: 6406191543 Enrollment ID: O20190826001133 |
News Archive
In a study of more than 1.3 million Kaiser Permanente members in Northern California that stretched over 10 years, researchers found that blacks, Latinos and Asians generally had lower risk of coronary heart disease compared to whites.
Results for a pilot registry on the management and treatment of atrial fibrillation in Europe were presented yesterday by the European Society of Cardiology. AF is the commonest cardiac rhythm disorder and each of us have a one-in-four lifetime risk of developing it. Statistics show that oral anticoagulant use has increased, but new oral anticoagulant use is still low. Authors also concluded that compliance with treatment guidelines for patients with the lowest and higher stroke risk scores remains suboptimal.
Jennerex, Inc., a clinical-stage biotherapeutics company focused on the development of first-in-class, targeted oncolytic products for cancer, today reported positive interim data from a pilot trial using JX-594 followed by sorafenib (Nexavar®) to treat liver cancer patients. The data were presented today at the Fourth Annual International Liver Cancer Association Conference in Montreal, Canada.
To combat the obesity epidemic, the National Institutes of Health is encouraging diverse scientific investigations through a new Strategic Plan for NIH Obesity Research.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr David J Itkin, MD 330 Borthwick Ave, Suite 210, Portsmouth, NH 03801-4174 Ph: (603) 433-8733 | Mr David J Itkin, MD 330 Borthwick Ave, Suite 210, Portsmouth, NH 03801-4174 Ph: (603) 433-8733 |
News Archive
In a study of more than 1.3 million Kaiser Permanente members in Northern California that stretched over 10 years, researchers found that blacks, Latinos and Asians generally had lower risk of coronary heart disease compared to whites.
Results for a pilot registry on the management and treatment of atrial fibrillation in Europe were presented yesterday by the European Society of Cardiology. AF is the commonest cardiac rhythm disorder and each of us have a one-in-four lifetime risk of developing it. Statistics show that oral anticoagulant use has increased, but new oral anticoagulant use is still low. Authors also concluded that compliance with treatment guidelines for patients with the lowest and higher stroke risk scores remains suboptimal.
Jennerex, Inc., a clinical-stage biotherapeutics company focused on the development of first-in-class, targeted oncolytic products for cancer, today reported positive interim data from a pilot trial using JX-594 followed by sorafenib (Nexavar®) to treat liver cancer patients. The data were presented today at the Fourth Annual International Liver Cancer Association Conference in Montreal, Canada.
To combat the obesity epidemic, the National Institutes of Health is encouraging diverse scientific investigations through a new Strategic Plan for NIH Obesity Research.
› Verified 6 days ago
Robert Millstein, MD Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: 100 Campus Dr, Suite 12, Portsmouth, NH 03801 Phone: 603-422-8208 Fax: 603-422-8219 | |
Mr. Hanad Omar, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 333 Borthwick Avenue, Portsmouth, NH 03801 Phone: 603-436-5110 | |
Thomas P Clairmont Jr., MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 330 Borthwick Ave, Suite 205, Portsmouth, NH 03801 Phone: 603-436-6115 Fax: 603-433-5567 | |
Daniel L Davies, DO Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 155 Borthwick Ave, Suite 202w, Portsmouth, NH 03801 Phone: 603-433-8434 Fax: 603-436-6608 | |
Brian Choi, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 333 Borthwick Ave, Portsmouth, NH 03801 Phone: 215-442-5031 | |
Dr. Sucharit Suresh Joshi, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 875 Greenland Rd, #c-10, Portsmouth, NH 03801 Phone: 603-436-3433 Fax: 603-427-5115 | |
Dr. Michael Casimir Danielski, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 875 Greenland Rd, #c-10, Portsmouth, NH 03801 Phone: 603-436-3433 Fax: 603-427-5115 |